Abstract
Malignant melanoma is a prime example of cancers that respond poorly to various treatment modalities including chemotherapy1. A number of chemotherapeutic agents have been shown recently to act by inducing apoptosis, a type of cell death antagonized by the bcl-2 gene2. Human melanoma expresses Bcl-2 in up to 90% of all cases3–7. In the present study we demonstrate that bcl-2 antisense oligonucleotide treatment improves the chemo-sensitivity of human melanoma grown in severe combined im-munodeficient (SCID) mice. Our findings suggest that reduction of Bcl-2 in melanoma, and possibly also in a variety of other tumors, may be a novel and rational approach to improve chemosensitivity and treatment outcome.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Boring, C.C., Squires, T.S., Tong, T. & Montgomery, S. Cancer statistics 1994. CA: Cancer J. Clinic 44, 7–26 (1994).
Hickman, J.A. Apoptosis and chemotherapy resistance. Eur. J. Cancer 32A, 921–926 (1996).
Cerroni, L., Soyer, H.P. & Kerl, H. bcl-2 protein expression in cutaneous malignant melanoma and benign melanocytic nevi. Am. J. Dermatopathol. 17, 7–11 (1995).
Morales-Ducret, C.R.J., van deRijn, M., LeBrun, D.P. & Smoller, B.R. bcl-2 expression in primary malignancies of the skin. Arch. Dermatol. 131, 909–918 (1995).
Plettenberg, A. et al. Human melanocytes and melanoma cells constitutively express the Bcl-2 proto-oncogene in situ and in cell culture. Am. J. Pathol. 146, 651–659 (1995).
Tron, V.A. et al. Immunohistochemical analysis of Bcl-2 protein regulation in cutaneous melanoma. Am. J. Pathol. 146, 643–650 (1995).
Grover, R. & Wilson, C.D. Bcl-2 expression in malignant melanoma and its prognostic significance. Eur. J. Surg. Oncol. 22, 347–349 (1996).
Stein, C.A. & Cheng, Y.-C. Antisense oligonucleotides as therapeutic agents–Is the bullet really magical? Science 261, 1004–1012 (1993).
Stein, C.A. Does antisense exist? Nature Med. 1, 1119–1121 (1995).
Christoffersen, R.E. Translating genomics information into therapeutics: A key role for oligonucleotides. Nature Biotechnol. 15, 483–484 (1997).
Monia, B.P., Johnston, J.F., Geiger, T., Muller, M. & Fabbro, D. Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase. Nature Med. 2, 668–675 (1996).
Comis, R.L. DTIC (NSC-45388) in malignant melanoma: A perspective. Cancer Treat Rep. 60, 165–176 (1976).
Henry, S.P., Monteith, D. & Levin, A.A. Antisense oligonucleotide inhibitors for the treatment of cancer. 2. Toxicological properties of phosphorothioate oligonucleotides. Anti-Cancer Drug Des. 12, 395–408 (1997).
Krieg, A.M. et al. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 374, 546–549 (1995).
Wooldridge, J.E., Ballas, Z., Krieg, A.M. & Weiner, G.J. Immunostimulatory oligonucleotides containing CpG motifs enhance the efficacy of monoclonal antibody therapy of lymphoma. Blood, 89, 2994–2998 (1997).
Webb, A. et al. BCL-2 antisense therapy in patients with non-Hodgkin lymphoma. Lancet 349, 1137–1141 (1997).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Jansen, B., Schlagbauer-Wadl, H., Brown, B. et al. bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice. Nat Med 4, 232–234 (1998). https://doi.org/10.1038/nm0298-232
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/nm0298-232
This article is cited by
-
Weight control interventions improve therapeutic efficacy of dacarbazine in melanoma by reversing obesity-induced drug resistance
Cancer & Metabolism (2016)
-
U1 Adaptor Oligonucleotides Targeting BCL2 and GRM1 Suppress Growth of Human Melanoma Xenografts In Vivo
Molecular Therapy - Nucleic Acids (2013)
-
Oblimersen in combination with temozolomide and albumin-bound paclitaxel in patients with advanced melanoma: a phase I trial
Cancer Chemotherapy and Pharmacology (2013)
-
Electroporation increases antitumoral efficacy of the bcl-2 antisense G3139 and chemotherapy in a human melanoma xenograft
Journal of Translational Medicine (2011)
-
Functional and prognostic relevance of the homeobox protein MSX2 in malignant melanoma
British Journal of Cancer (2011)